BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET

About this update from Biomarin Pharmaceutical Inc.

SAN RAFAEL, Calif. , July 30, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Alexander Hardy, President and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, August 6, 2026, at 4:30 p.m. ET to discuss second quarter 2026 financial results and provide a general business update. Dial-in Number   U.S. / Canada Dial-in Number: 800-715-9871 International Dial-in Number: 646-307-1963 Conference Call ID: 3551298  U.S. / Canada Replay Dial-in Number: 800-770-2030 International Replay Dial-in Number: 609-800-9909 Playback ID: 3551298  Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website,  https://investors.biomarin.com/ . A replay of the call will be archived on the site for one week following the call. About BioMarin BioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. To learn more, please visit www.biomarin.com .  Contacts: Investors Media Traci McCarty Marni Kottle BioMarin Pharmaceutical Inc. BioMarin Pharmaceutical Inc. (415) 455-7558 (650) 374-2803   View original content to download multimedia: https://www.prnewswire.com/news-releases/biomarin-to-host-second-quarter-2026-financial-results-conference-call-and-webcast-on-thursday-august-6-2026-at-430pm-et-302838363.html SOURCE BioMarin Pharmaceutical Inc.

View stock analysis, news, and events for Biomarin Pharmaceutical Inc.